21037 ⎘
Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof; Enzymes; Proenzymes; Derivatives thereof; Hydrolases (3) acting on peptide bonds (3.4); Serine endopeptidases (3.4.21) Kallikrein (3.4.21.34 or 3.4.21.35)
COMPOSITIONS AND METHODS FOR GENOME EDITING
#2DOSAGE FORMS OF TISSUE KALLIKREIN 1
#3INTRAVENOUS COMPOSITIONS OF TISSUE KALLIKREIN-1 AND RELATED METHODS
#4TISSUE KALLIKREIN-1 FOR TREATING PREGNANCY DISORDERS
#5Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of ANG, ANGPT1, VEGFA, FGF1, HIF1a, HGF, SDF1, KLK4, PDGFC, PROK1, and PROK2 genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-ANG, or Escherichia coli strain SCS110-AF/VTvaf17-ANGPT1, or Escherichia coli strain SCS110-AF/VTvaf17-VEGFA, or Escherichia coli strain SCS110-AF/VTvaf17-FGF
#6DOSAGE FORMS OF TISSUE KALLIKREIN 1
#7ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
#8Macrophage Stimulating 1 Receptor (MST1R) Variants And Uses Thereof
#9TISSUE KALLIKREIN-1 FOR TREATING CHRONIC KIDNEY DISEASE
#10METHODS OF TREATING NEUROLOGICAL DISORDERS
#11TUNEABLE DELIVERY OF NANOPARTICLE BOUND ACTIVE PLASMIN FOR THE TREATMENT OF THROMBOSIS
#12ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME
#13Methods of treating neurological disorders
#14Methods of treating neurological disorders
#15Dosage forms of tissue kallikrein 1
#16Macrophage stimulating 1 receptor (MST1R) variants and uses thereof
#17Antidotes for factor Xa inhibitors and methods of using the same
#18Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis
#19Antidotes for factor Xa inhibitors and methods of using the same
#20Use of serine protease inhibitors in the treatment of skin diseases
#21FORMULATIONS OF HUMAN TISSUE KALLIKREIN-1 FOR PARENTERAL DELIVERY AND RELATED METHODS
#22Methods and materials for modulating resistance to apoptosis using KLK6 antisense and MIRNA molecules
#23Antidotes for factor Xa inhibitors and methods of using the same
#24Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis
#25Human tissue kallikrein 1 glycosylation isoforms
#26Pegylated tissue kallikrein, and preparation method therefor and uses thereof
#27Antidotes for factor Xa inhibitors and methods of using the same
#28Antidotes for factor XA inhibitors and methods of using the same
#29Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
#30Human tissue kallikrein 1 glycosylation isoforms
#31Antidotes for factor Xa inhibitors and methods of using the same
#32USE OF SERINE PROTEASE INHIBITORS IN THE TREATMENT OF SKIN DISEASES
#33COMPOSITIONS AND METHODS FOR TREATING DIABETES
#34Antidotes for factor Xa inhibitors and methods of using the same
#35Antidotes for factor XA inhibitors and methods of using the same
#36Methods for increasing susceptibility to apoptosis by administering an inhibitor of kallikrein 6 polypeptide activity
#37FORMULATIONS OF HUMAN TISSUE KALLIKREIN-1 FOR PARENTERAL DELIVERY AND RELATED METHODS
#38METHODS OF DIAGNOSIS AND TREATMENT FOR METABOLIC DISORDERS
#39Antidotes for factor Xa inhibitors and methods of using the same
#40Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides
#41TISSUE KALLIKREIN FOR THE TREATMENT OF PARKINSON'S DISEASE
#42Antidotes for factor Xa inhibitors and methods of using the same
#43TISSUE KALLIKREIN FOR THE TREATMENT OF HUNTINGTON'S DISEASE
#44TISSUE KALLIKREIN FOR THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER
#45Methods for modulating resistance to apoptosis using KLK6
#46TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC Beta-CELL DYSFUNCTION AND FOR Beta-CELL PROLIFERATION
#47TISSUE KALLIKREIN FOR THE TREATMENT OF PARKINSON'S DISEASE
#48USE OF SERINE PROTEASE INHIBITORS IN THE TREATMENT OF SKIN DISEASES
#49Method for identifying a non-anticoagulant sulfated polysaccharide which enhances blood coagulation dependence on FXI
#50Antidotes for factor Xa inhibitors and methods of using the same
#51Tissue kallikrein for the treatment of diseases associated with amyloid protein
#52Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents
#53METHODS OF DIAGNOSIS AND TREATMENT FOR METABOLIC DISORDERS
#54METHOD AND PRODUCT FOR LOCATING AN INTERNAL BLEEDING SITE
#55THERAPEUTIC USES OF GLANDULAR KALLIKREIN
#56Antidotes for factor Xa inhibitors and methods of using the same
#57Therapeutic uses of glandular kallikrein
#58Compositions and methods for locating an internal bleeding site
#59Therapeutic uses of kallikreins
#60Method and product for locating an internal bleeding site